Core Viewpoint - The company, Haijia Medical (06078), anticipates a revenue decline of approximately 9% to 10% for 2025, with projected revenues between RMB 4.0 billion and 4.05 billion [1] Financial Performance Summary - The expected net profit for 2025 is projected to be between RMB 1.4 billion and 2.0 billion, reflecting a significant decrease of approximately 66% to 76% primarily due to goodwill impairment [1] - Adjusted net profit is forecasted to be between RMB 4.5 billion and 4.9 billion, indicating a year-on-year decline of about 19% to 25% [1] - The net cash generated from operating activities is expected to be between RMB 9.4 billion and 10.0 billion, showing an increase of approximately 33% to 41% year-on-year [1] Factors Influencing Performance - The decline in revenue, net profit, and adjusted net profit is attributed to industry and macroeconomic impacts, as well as increased startup costs and depreciation expenses from newly opened hospitals [1] - The net profit decrease for the year ending December 31, 2025, is also significantly influenced by the goodwill impairment provision related to Etern Group Ltd. [1] - The company has conducted a careful assessment of its operational and financial performance, as well as the future prospects of its business, to determine the necessity and amount of the impairment and provision [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Hygeia Healthcare Holdings Co., Limited （ 於 公 司 ） 海 吉 亞 醫 療 控 股 有 限 公 司 開 曼 群 島 註 冊 成 立 的 有 限 （股 份 代 號：6078） 盈利預警 海吉亞醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571 章《證券及期貨條例》第XIVA部項下之內幕消息條文（定義見上市規則）作出本 公告。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資 者，基於對本集團截至二零二五年十二月三十一日止年度未經審核綜合管理 賬目（按國際財務報告準則(IFRS)編製）的初步評估及董事會目前可得資料，預 計： – 1 – 股東及本公司潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 海吉亞醫療控股有限公司 主席 (i ...

Core Viewpoint - Southbound funds have reduced their holdings in Haijia Medical (06078.HK) by 168,400 shares on January 28, with a total net reduction of 2.18 million shares over the past five trading days and 8.97 million shares over the last twenty trading days [1] Group 1: Southbound Fund Activity - Southbound funds have reduced their holdings in Haijia Medical for 4 out of the last 5 trading days, totaling a net reduction of 218,000 shares [1] - Over the past 20 trading days, there have been 16 days of reductions, with a cumulative net decrease of 8.97 million shares [1] - Currently, southbound funds hold 202 million shares of Haijia Medical, representing 32.62% of the company's total issued ordinary shares [1] Group 2: Company Overview - Haijia Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments, with the hospital business segment focusing on comprehensive cancer diagnosis and treatment services [1] - The other business segment is involved in various other operations, primarily within the domestic market [1]

Core Viewpoint - Southbound funds have reduced their holdings in Haijia Medical (06078.HK) by 511,400 shares on January 9, indicating a trend of net selling over recent trading days [1] Group 1: Shareholding Changes - In the last 5 trading days, southbound funds have net sold a total of 2,574,400 shares of Haijia Medical [1] - Over the past 20 trading days, there have been 14 days of net selling, with a cumulative reduction of 4,068,600 shares [1] - Currently, southbound funds hold 206 million shares of Haijia Medical, representing 33.33% of the company's total issued ordinary shares [1] Group 2: Company Overview - Haijia Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments: the hospital business segment focuses on comprehensive cancer diagnosis and treatment services, including multiple oncology medical services such as radiotherapy, chemotherapy, surgery, and targeted therapy [1] - The other business segment is engaged in various other operations, with the company primarily conducting its business in the domestic market [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 公司名稱: 海吉亞醫療控股有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Hai Ji Ya Medical (06078.HK) by 617,200 shares on January 2, with a total net reduction of 4,525,200 shares over the past five trading days [1] - Over the last 20 trading days, there have been 11 days of net reductions by southbound funds, totaling 1,763,000 shares [1] - As of now, southbound funds hold 208 million shares of Hai Ji Ya Medical, which represents 33.64% of the company's total issued ordinary shares [1] Group 2 - Hai Ji Ya Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments, with the hospital business segment focusing on comprehensive cancer diagnosis and treatment services, including radiation therapy, chemotherapy, surgery, and targeted therapy [1] - The other business segment is engaged in various other operations, with the company primarily conducting its business in the domestic market [1]

Group 1 - The company, Haijia Medical (06078.HK), announced a share buyback on December 31, spending HKD 1.242 million to repurchase 100,000 shares at a price of HKD 12.42 per share [1]

Core Viewpoint - Haijia Medical (06078) announced a share buyback plan, intending to repurchase 100,000 shares at a cost of HKD 1.242 million by December 31, 2025 [1] Group 1 - The company will spend HKD 1.242 million for the buyback [1] - The buyback involves repurchasing 100,000 shares [1] - The completion date for the buyback is set for December 31, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 海吉亞醫療控股有限公司 呈交日期： 2025年12月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： 若股份曾以超過一個每股價 ...

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Hai Ji Ya Medical (06078.HK) by 1.0894 million shares on December 30, 2025, marking a total net reduction of 4.2976 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings in Hai Ji Ya Medical on 11 occasions, resulting in a cumulative net reduction of 1.3302 million shares [1] - As of now, southbound funds hold 209 million shares of Hai Ji Ya Medical, which accounts for 33.74% of the company's total issued ordinary shares [1] Group 2 - The company, Hai Ji Ya Medical Holdings Limited, primarily provides medical services through two business segments [2] - The hospital business segment focuses on offering comprehensive diagnosis and treatment services for cancer, including multiple cancer medical services such as radiotherapy, chemotherapy, surgery, and targeted therapy [2] - The other business segment mainly engages in various other operations, with the company primarily operating in the domestic market [2]